

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Maertens

Atty. Ref.: **620-149**

Continuation of Serial No. **09/308,935**

Group:

Filed: **July 9, 2001**

Examiner:

For: **PEPTIDE ANTAGONISTS OF DP TRANSCRIPTION
FACTORS**

* * * * *

July 9, 2001

Assistant Commissioner for Patents
Washington, DC 20231

Sir:


REQUEST

The Office is requested to use the computer-readable copy of the Sequence Listing from the parent Application No. 09/308,935. The attached paper copy of the Sequence Listing is the same as the paper and computer-readable copies of the Sequence Listing filed in the parent Application No. 09/308,935, with the Letter dated December 23, 1999. No new matter has been added.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____



B. J. Sadoff

Reg. No. 36,663

BJS:eaw

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

SEQUENCE LISTING

<110> La Thangue, Nicholas B
Bandara, Lasantha R

<120> Peptide antagonists of DP transcription factors

<130> 620-67

<140> US 09/308,935

<141> 1999-05-27

<150> PCT/GB97/03506

<151> 1997-12-22

<150> GB 9626589.7

<151> 1996-12-20

<160> 18

<170> PatentIn Ver. 2.1

<210> 1

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 1

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Asn | Ile | Arg | Arg | Arg | Val | Tyr | Asp | Ala | Leu | Asn | Val | Leu | Met | Ala |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Asn | Ile | Ile | Ser | Lys | Glu | Lys | Lys | Glu | Ile | Lys | Trp | Ile | Gly | Leu |
| | | | 20 | | | | 25 | | | | | | | 30 | |

| | | | | |
|-----|-----|-----|-----|-----|
| Pro | Thr | Asn | Ser | Ala |
| | | | | 35 |

<210> 2

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 2

| | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Val | Leu | Met | Ala | Met | Asn | Ile | Ile |
| 1 | | | | | | 5 | | |

099000147.070901

<210> 3
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

<400> 3
 Arg Arg Arg Val Tyr Asp Ala Leu Asn Val Leu Met Ala Met Asn Ile
 1 5 10 15

Ile Ser Lys

<210> 4
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

<400> 4
 Asn Val Leu Met Ala Met Asn Ile Ile Ser Lys Glu Lys Lys Glu Ile
 1 5 10 15

Lys Trp Ile Gly
 20

<210> 5
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

<400> 5
 Arg Val Tyr Asp Ala Leu Asn Val Leu Met Ala Met Asn Ile Ile Ser
 1 5 10 15

050047-0901

<210> 6
 <211> 30
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

<400> 6
 Tyr Asp Ala Leu Asn Val Leu Met Ala Met Asn Ile Ile Ser Lys Glu
 1 5 10 15

Lys Lys Glu Ile Lys Trp Ile Gly Leu Pro Thr Asn Ser Ala
 20 25 30

<210> 7
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

<400> 7
 Ala Leu Asn Val Leu Met Ala
 1 5

<210> 8
 <211> 16
 <212> PRT
 <213> Drosophila melanogaster

<400> 8
 Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
 1 5 10 15

<210> 9
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

<400> 9
 Arg Arg Arg Val Tyr Asp Ala Leu Asn Val Leu
 1 5 10

005020" 24T00550

<400> 13
Asn Leu Val Gln Arg Asn Arg Gln Ala Glu Gln Gln Ala Arg Arg
1 5 10 15

Ile Ser Lys

<210> 17
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Mutant peptide

<400> 17

Arg Arg Arg Val Tyr Asp Ala Arg Asn Val Arg Met Ala Met Asn Ile
 1 5 10 15

Ile Ser Lys

<210> 18
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
 Oligonucleotide

<400> 18

cgtgtctacg atggcggaaa tgtgctaata

30

05900147-070901
 T06020-24T00650

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: Prolifix Limited
(B) STREET: 91 Milton Park
(C) CITY: Abingdon
(D) STATE: Oxfordshire
(E) COUNTRY: United Kingdom
(F) POSTAL CODE (ZIP): OX14 4RY

(A) NAME: LA THANGUE, Nicholas Barrie
(B) STREET: Institute of Biomedical and Life Sciences,
Davidson Building, University of Glasgow
(C) CITY: Glasgow
(E) COUNTRY: United Kingdom
(F) POSTAL CODE (ZIP): G12 8QQ

(A) NAME: BANDARA, Lasantha Ranasinghe
(B) STREET: Prolifix Limited, 91 Milton Park
(C) CITY: Abingdon
(D) STATE: Oxfordshire
(E) COUNTRY: United Kingdom
(F) POSTAL CODE (ZIP): OX14 4RY

(ii) TITLE OF INVENTION: Peptide antagonists of DP transcription factors

(iii) NUMBER OF SEQUENCES: 18

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

(v) CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/GB97/03506

(vi) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: GB 9626589.7
(B) FILING DATE: 20-DEC-1996

00000147 070901

(i) SEQUENCE CHARACTERISTICS:

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Pro Thr Asn Ser Ala
35

(i) SEQUENCE CHARACTERISTICS:

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Asn Val Leu Met Ala Met Asn Ile Ile
1 5

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

090914Z070600

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Arg Arg Arg Val Tyr Asp Ala Leu Asn Val Leu Met Ala Met Asn Ile
1 5 10 15

Ile Ser Lys

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Asn Val Leu Met Ala Met Asn Ile Ile Ser Lys Glu Lys Lys Glu Ile
1 5 10 15

Lys Trp Ile Gly
20

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Arg Val Tyr Asp Ala Leu Asn Val Leu Met Ala Met Asn Ile Ile Ser
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Tyr Asp Ala Leu Asn Val Leu Met Ala Met Asn Ile Ile Ser Lys Glu
1 5 10 15
Lys Lys Glu Ile Lys Trp Ile Gly Leu Pro Thr Asn Ser Ala
20 25 30

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Ala Leu Asn Val Leu Met Ala
1 5

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

Arg Arg Arg Val Tyr Asp Ala Leu Asn Val Leu
1 5 10

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Glu Lys Lys Glu Ile Lys Trp Ile Gly Leu Pro Thr Asn Ser Ala
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

Arg Arg Val Tyr Asp Ala Leu Asn Val Leu Met Ala Met Asn
1 5 10

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

Asn Glu Ser Ala Tyr Asp Gln Lys Asn Ile Arg Arg
1 5 10

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids

T06020" 44T00650

- (B) TYPE: amino acid
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

Asn Leu Val Gln Arg Asn Arg Gln Ala Glu Gln Gln Ala Arg Arg
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 14:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

Glu Val Glu Arg Gln Arg Arg Leu Glu Arg Ile Lys Gln Lys Gln
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 15:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

Arg Arg Arg Ala Tyr Asp Ala Leu Asn Ala Leu Met Ala Met Asn Ile
1 5 10 15

Ile Ser Lys

(2) INFORMATION FOR SEQ ID NO: 16:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

Arg Ala Arg Val Tyr Ala Ala Leu Asn Val Leu Met Ala Met Asn Ile
1 5 10 15

Ile Ser Lys

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

Arg Arg Arg Val Tyr Asp Ala Arg Asn Val Arg Met Ala Met Asn Ile
1 5 10 15

Ile Ser Lys

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

CGTGTCTACG ATGGCGGAAA TGTGCTAATG

30